The innovative drug sector has recently emerged as a significant high-growth theme within the A-share market, driven by multiple favorable catalysts. On the morning of May 7, 2026, the sector experienced another strong upward movement, boosting trading activity in core products like the Huatai Bairui Hang Seng Innovation Drug ETF (520500) and reinforcing the trend of valuation recovery. According to Wind data, as of 10:10 today, the intraday trading volume for the Huatai Bairui Hang Seng Innovation Drug ETF (520500) had already reached 450 million yuan.
A key driver behind this sector recovery is the anticipated positive impact from a major industry event. The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting is scheduled to take place in Chicago from May 29 to June 2. Chinese innovative drug companies have achieved a new milestone this year, with 12 companies and 13 studies selected for the "Late-Breaking Abstract" (LBA) category, setting a historical record. Furthermore, a total of 94 original studies have been accepted for oral presentations, reflecting rapid growth over the past three years. As more high-quality clinical data gains international recognition, the global competitiveness and market realization capabilities of China's innovative drugs continue to strengthen, providing solid support for the sector's long-term positive outlook.
Beyond the expectations surrounding the major conference, the release of first-quarter 2026 financial results has further validated the growth narrative of the innovative drug sector from a profitability perspective. Following the conclusion of the quarterly reporting season, several innovative drug companies reported impressive operational performances. Data indicates that among the constituents of the Hang Seng Innovation Drug Index, six companies have disclosed their Q1 reports, with five achieving growth in both revenue and net profit. Leading companies within the sector delivered particularly strong results, with one major firm reporting quarterly product revenue exceeding 3.8 billion yuan, a year-on-year increase of over 50%, demonstrating the successful execution of its dual-growth strategy and providing clearer evidence of an industry-wide commercial profitability inflection point.
The robust first-quarter performance of drug companies reflects the heated trend of domestic innovative drugs expanding overseas. Data from the National Medical Products Administration shows that in the first quarter of this year, the total value of out-licensing deals for Chinese innovative drugs surpassed 60 billion US dollars, approaching half of the total transaction value for the entire year of 2025. This acceleration in global commercialization is opening up new growth avenues for the industry's long-term development.
Bolstered by both positive news catalysts and solid earnings validation, market confidence has significantly improved, leading to sustained capital inflows into the innovative drug sector. Wind data shows that the Huatai Bairui Hang Seng Innovation Drug ETF (520500), the only product in the market tracking the Hang Seng Innovation Drug Index, has recorded weekly net capital inflows for six consecutive weeks (from March 30, 2026, to May 6, 2026), accumulating total inflows of 350 million yuan. This has helped push its total asset size and share count to 2.429 billion yuan and 1.579 billion shares, respectively.
It is reported that the Hang Seng Innovation Drug Index, which the Huatai Bairui Hang Seng Innovation Drug ETF (520500) closely tracks, invests in 40 leading innovative drug companies listed in Hong Kong through a QDII mechanism. The index maintains 100% purity in innovative drugs, focusing on areas such as biopharmaceuticals, chemical pharmaceuticals, and active pharmaceutical ingredients. This ETF features a large scale, high liquidity, and supports intraday T+0 trading. Against a backdrop of catalysts from global academic conferences, ongoing strong business development activity, and a potential fundamental profitability inflection point for innovative drug companies, it may serve as an efficient tool for gaining exposure to opportunities in the Hong Kong-listed innovative drug sector.
The manager of the Huatai Bairui Hang Seng Innovation Drug ETF (520500), Huatai Bairui Fund, was one of China's first ETF managers and has been dedicated to the field of index investing for over 19 years. It has developed transparent, easily tradable, and low-cost index tools for investors, such as the Huatai Bairui CSI 300 ETF (510300) and the Huatai Bairui A500 ETF (563360). By the end of 2025, the company's ETF products had generated cumulative profits exceeding 164 billion yuan for holders over the preceding two years, making it one of only four fund companies in the entire market to achieve cumulative profits of over 100 billion yuan during that period. In terms of fees, ETFs covering 77.8% of the company's assets under management adopt the lowest tier fee structure currently available for equity index funds in the market.
A MACD golden cross signal has formed, indicating positive momentum for these stocks.